<DOC>
	<DOCNO>NCT03085368</DOCNO>
	<brief_summary>This randomize controlled trial HER-2 positive breast cancer patient treat lapatinib paclitaxel v herceptin paclitaxel sequential synchronous anthracycline</brief_summary>
	<brief_title>A Randomized Controlled Trial HER-2 Positive Breast Cancer Patients Treated With Lapatinib v Herceptin</brief_title>
	<detailed_description>This randomize controlled trial HER-2 positive breast cancer patient treat lapatinib paclitaxel v herceptin paclitaxel sequential synchronous anthracycline . Safety efficacy primary endpoint . The positive expression HER2 confirm postoperative pathology patient breast adenocarcinoma ( IDC ) . Patients receive chemotherapy target anti HER2 therapy . In study , non inferiority design method , accord wish patient sign informed consent , randomly group , total 482 patient enrolled trial group : control group =1:1 . The subject follow total 1 year , disease progress , toxicity tolerate . We want study 84 month . The follow-up period 5 year ( first adjuvant treatment time last follow-up ) researcher decide end study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>1. first diagnosis invasive breast cancer , confirm histology cytology , surgical resection primary lesion receive anti breast cancer treatment ; 2. female patient , age 18 year less 80 year age ; 3. surgical resection primary tumor pathological examination , show HER2 positive ( defined immunohistochemistry [ IHC ] 3+ fluorescence situ hybridization ( FISH ) positive ) ; 4. hormone receptor status know , lymph node positive sentinel lymph node negative high risk factor 5. eastern oncology cooperative group ( ECOG ) patient physical status score 0 2 ; 6. baseline LVEF &gt; 50 % 7. relevant institutional review board ( IRB ) independent ethic committee ( IEC ) write informed consent 1. subject pregnancy lactation ; 2. pregnant woman may within first 7 day pregnancy test positive ( urine serum ) . 3. receive chemotherapy , endocrine anti HER2 antitumor therapy ; 4. congestive heart failure , unstable angina , heart failure myocardial infarction disease ; 5. invasive tumor ( include second primary breast cancer ) , may affect outcome evaluation program compliance ; treatment patient disease free survival least 5 year select ; 6. chronic liver disease patient liver dysfunction / clinical manifestation : serum total bilirubin &gt; 2.5 * ULN ; INR = 1.5 bilirubin . serum ALT AST &gt; * 3 * ULN ; alkaline phosphatase &gt; 2.5 * ULN ; ALT AST gradually increase , gradually increase fatigue , nausea vomiting , fever , right upper quadrant pain tenderness 7. hematopoietic dysfunction , define follow : neutrophil count ( ANC ) &lt; 1.5 * 109/L ; platelet &lt; 100 * 109/L ; hemoglobin &lt; 9 g/dL ; 8. serious disease , include : congestive heart failure ( heart function NYHA grade II , III , IV ) occur within 6 month congestive heart failure , unstable angina , arrhythmia , myocardial infarction patient ca n't control severe cardiovascular disease ; breathe rest need oxygen therapy ; serious infection ; uncontrolled diabetes ; 9. serious psychological mental abnormality , estimate participant participate study strong ; 10. know study drug allergy ; 11. past 30 day participate study drug clinical trial . 1 , fail complete clinical trial least 1 cycle accord program , carry safety efficacy evaluation 2 , serious violation research program , accordance prescribe dose , method course medication . Patients receive lapatinib treatment , predetermine end end point , development unacceptable toxicity , withdrawal consent , illness death , appear subject .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>her-2 positive</keyword>
	<keyword>lapatinib</keyword>
	<keyword>herceptin</keyword>
</DOC>